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Abstract
Background: Quantifying resource utilization in the inpatient care of congenital heart diease is clinically relevant.
Our purpose is to measure the investment of inpatient care resources to achieve survival in hypoplastic left heart
syndrome (HLHS), and to determine how much of that investment occurs in hospitalizations that have a fatal
outcome, the mortality-related resource utilization fraction (MRRUF).
Methods: A collaborative administrative database, the Pediatric Health Information System (PHIS) containing data
for 43 children’s hospitals, was queried by primary diagnosis for HLHS admissions of patients ≤21 years old during
2004–2013. Institution, patient age, inpatient deaths, billed charges (BC) and length of stay (LOS) were recorded.
Results: In all, 11,122 HLHS admissions were identified which account for total LOS of 277,027 inpatient-days and
$3,928,794,660 in BC. There were 1145 inpatient deaths (10.3 %). LOS was greater among inpatient deaths than
among patients discharged alive (median 17 vs. 12, p < 0.0001). BC were greater among inpatient deaths than
among patients discharged alive (median 4.09 × 105 vs. 1.63 × 105, p < 0.0001). 16 % of all LOS and 21 % of all BC
were accrued by patients who did not survive their hospitalization. These proportions showed no significant
change year-by-year. The highest volume institutions had lower mortality rates, but there was no relation between
institutional volume and the MRRUF.
Conclusions: These data should alert providers and consumers that current practices often result in major resource
expenditure for inpatient care of HLHS that does not result in survival to hospital dismissal. They highlight the need
for data-driven critical review of standard practices to identify patterns of care associated with success, and to
modify approaches objectively.
Keywords: Hypoplastic left heart syndrome, Pediatric cardiology, Congenital heart disease, Mortality-related
resource utilization fraction, Outcomes
Background
Hypoplastic left heart syndrome (HLHS) remains one of
the most high-risk congenital heart diseases in spite of ad-
vances in surgical techniques and perioperative manage-
ment. Three decades ago the majority of babies born with
HLHS died within the first days or few weeks of life, and
compassionate care was the only option for this disease.
In the current era, many infants with HLHS undergo a
series of palliative surgeries [1]. The first of these, the Nor-
wood Operation, usually takes place in the first week of
life. In this procedure, the hypoplastic aorta is recon-
structed to yield an unobstructed neo-aorta arising from
the right ventricle, a shunt is placed to provide pulmonary
arterial flow, and the atrial septum is resected. At approxi-
mately 4–6 months, a bidirectional superior cavopulmon-
ary shunt (Glenn) is constructed to replace the initial
shunt, which is by then outgrown. A Fontan operation,
generally done at 2–4 years, incorporates inferior vena
cava flow directly into the pulmonary circulation. This
conventional palliation may ultimately fail, especially in
older children and young adults, and cardiac transplant-
ation may be considered at that point.
In the current era, staged surgical palliation is stand-
ard of care for HLHS in most institutions in North
America (2320 Norwood operations reported by the
Society of Thoracic Surgeons Congenital Heart Surgical
Database in 2009) [1]. There is attrition around and
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between palliative surgeries, resulting in expected
survival rate of 70 % at age 5 years [1, 2]. In 2011,
Dean et al. documented mean hospital charges of
$214,680, $82,174, and $79,549 for Norwood, Glenn,
and Fontan palliations, respectively [3]. Efforts to
achieve durable survival through staged palliation re-
quire sophisticated costly inpatient care [4–6]. Sur-
vivorship is improving [1, 6, 7], but the degree to
which investment in this care fails to produce desired
outcome is seldom studied. Some disagreements per-
sist among physicians regarding the relative merits of
encouraging parents to pursue high intensity surgical
management for HLHS in the hope of a good out-
come versus encouraging parents to accept a fatal
neonatal outcome by providing comfort measures
only [8–12].
We have developed a potentially enlightening index,
the mortality-related resource utilization fraction
(MRRUF), the resources expended in inpatient care
which the patient does not survive divided by all in-
patient care resources expended regardless of survival.
The MRRUF can be conceived based on any type of
measurable investment in care. True costs might be
ideal, but are difficult to acquire consistently from
large multi-institutional databases, so this investiga-
tion will focus on time (length of hospital stay) and
money (billed charges). Our purpose is to measure
the investment of inpatient care resources in the care
of HLHS, and determine how much of that invest-
ment takes place during hospitalizations that have a
fatal outcome.
Methods
The Pediatric Health Information System (PHIS, Chil-
dren’s Hospital Association, Overland Park, Kansas) is
an administrative database containing comprehensive in-
patient, observation, ambulatory surgery, and emergency
department data from 43 not-for-profit children’s hospi-
tals belonging to an alliance of free-standing pediatric
hospitals. For the purposes of external benchmarking,
participating hospitals provide discharge/encounter data,
including demographics, International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
diagnoses, and procedures, length of stay, and discharge
status (discharged to home, rehabilitation facility, nurs-
ing facility, or inpatient death). Data are deidentified at
the time of data submission, and are subjected to bi-
monthly coding consistency reviews and quarterly data
quality reports to ensure data quality, through a joint
effort between the Child Health Corporation of America
and participating hospitals.
The PHIS database was queried for patients ≤21 years
old with the primary diagnosis of HLHS who were
admitted for inpatient care during 2004–2013. There
were no exclusions, and no other inclusion criteria.
Institution, patient age at hospital admission, inpatient
deaths, billed charges (BC) and length of stay (LOS)
were recorded. Data acquisition was at the hospital ad-
mission level and not the person level. The methodology
did not account for multiple occasions of admission of
the same person or for transfers within or outside of
PHIS. Measures of central tendency for the data were
presented as mean ± standard deviation, median, and
interquartile range. The mortality-related resource
utilization fraction (MRRUF) was calculated based on
BC and on LOS:
LOS‐based MRRUF ¼ LOS for hospitalizations resulting in fatality
Total LOS
ð1Þ
BC‐based MRRUF ¼ BC for hospitalizations resulting in fatality
Total BC
ð2Þ
MRRUF was calculated for the total study population,
and year-by-year, and institution-by-institution in the
LOS and BC domains.
Volume of admissions for HLHS (number of admissions
at any participating hospital in 10 year sample/10) and
mortality rates (number of deaths/number of admissions)
were calculated for each institution. Due to concerns that
three institutions with extremely small volume and no
mortality likely were nonrepresentative of the usual prac-
tices and patterns of care for HLHS, those were excluded.
The potential relations of MRRUF (LOS and BC) and of
the mortality rate to institutional volume and to year of
admission were assessed using least squares regression
analysis and Spearman’s rank correlation for the sample
including the remaining 40 institutions.
The study population was divided into 5 age groupings
for comparison, age <1, 1, 2–4, 5–13, and 14–21 years.
Chi square tests were applied to compare mortality rates
and multiple comparisons made among the groups. To
compare MRRUF (very non-normally distributed) among
the 5 age groupings, the Mann–Whitney U test was ap-
plied. Levels of statistical significance were p < 0.05, unless
corrected for circumstances of multiple comparisons, as
identified in the results. Statistical analysis was done using
commercially available software (Minitab 16.1, Minitab,
Inc., State College, PA, USA).
Results
In total, 11,122 HLHS admissions (mean 259 ± 181 per
institution) were identified which account for total LOS
of 277,027 inpatient-days and $3,928,794,660 in BC.
There were 1145 inpatient deaths (10.3 %). The mean,
interquartile range, and median were: for patient age
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1.13, 0–2, and 0 years, for LOS 24.9, 6–29, and 12 days,
and for BC ($) 353,000, 86,000-392,000, and 175,000.
There was a significant negative correlation between the
year and the inpatient mortality rate (adjusted r2 = 0.060,
p < 0.001, Fig. 1). Table 1 shows the characteristics of the
dataset from which MRRUF was derived. Age at hospital
admission was lower, LOS was higher, and BC were
higher among non-survivors than among survivors. LOS
was greater among inpatient deaths than among patients
discharged alive (median 17 vs. 12, p < 0.0001). BC were
greater among inpatient deaths than among patients dis-
charged alive (median 4.09 × 105 vs. 1.63 × 105, p < 0.0001).
There was a significant negative correlation between
institutional volume of admission for HLHS and
inpatient mortality rate; high volume institutions had
lower hospital mortality than institutions in all lower
volume categories (Fig. 1). Inpatient mortality rate was
remarkably higher among patients under a year old and
those 15 years old or older at hospital admission than it
was among those of intermediate age. There was higher
mortality among the oldest and the youngest patients,
and the mortality was relatively constant at lower levels
at intermediate ages (Fig. 1).
Sixteen percent of all LOS and 21 % of all BC were ac-
crued by patients who did not survive their hospitalization.
There was no significant association between calendar year
and MRRUF, either in the billed charges domain or in the
length of stay domain. These MRRUF proportions year by
year are shown in Fig. 2. MRRUF also did not vary signifi-
cantly with institutional volume, even when potentially out-
lying extreme low volume institutions were excluded.
Figure 3 shows the lack of significant association between
institutional volume and MRRUF either in the billed
charges domain or in the length of stay domain. The rela-
tion between institutional volume and MRRUF was insig-
nificant, (Spearman’s rho = 0.039, p = 0.080 for billed
charges, and rho = 0.097, p = 0.54 for length of stay).
MRRUF was high in the oldest patients, but those
under a year old also were found to have high MRRUF
relative to the intermediate age categories (Fig. 4). Com-
parisons of inpatient mortality rates and MRRUF are
shown in Table 2.
Discussion
As others have also documented [1, 5, 6], we observed
that mortality rates in the hospital for children with
HLHS have fallen in recent years, but remain substantial.
The mortality is high in the very young, the age at which
the Norwood operation and cavopulmonary connection
are done. This is consistent with published data indicat-
ing that the Norwood operation is associated with
significant risk of death [7], and that the interstage
period between Norwood and cavopulmonary connec-
tion is a time of substantial attrition [13–15]. We also
found that late childhood is a time of high MRRUF in
HLHS, and this coincides with a time when failing Fon-
tan physiology is well known to occur [16, 17]. Relative
to these higher risk early and late periods in the modi-
fied natural history of HLHS, we observed lower mortal-
ity and MRRUF at ages during which the cavopulmonary
connection and Fontan procedures occur, as well as dur-
ing the early post-Fontan timeframe.
Fig. 1 Mortality rates for Hypoplastic Left Heart Syndrome from the
Pediatric Health Information System 2004–2013. Mortality rates per
hospitalization for hypoplastic left heart syndrome have fallen between
2004 and 2013 (upper panel). The middle panel shows the significant
negative correlation between institutional volume of admission for
hypoplastic left heart syndrome and inpatient mortality rate. The lower
panel displays the remarkable variation in inpatient mortality rate with
age at admission
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Even as mortality rates gradually decline, the costs of
care for HLHS remain high [3, 4]. Our findings confirm
that investment of resources in inpatient care of HLHS
is high, and is disproportionately so among those who
do not survive their hospitalization. Inpatient death is
not the only adverse outcome known to be associated
with HLHS. The findings identified here using inpatient
death as a crude marker of poor outcome may substan-
tially underestimate a larger association of more general
poor outcomes in HLHS. Recent investigations have
Table 1 Inpatient characteristics of hospitalizations with hypoplastic left heart syndrome (Pediatric Health Information System,
2004–2013)
Number of admissions Hospitalization duration (days) Billed charges ($ × 106) Hospital deaths
Hospital volume (Admissions/10 years)
< 100 398 8260 138.9 59
100–199 1441 44,777 628.9 199
200–299 2528 64,295 895.1 286
300–499 3652 95,722 1429.1 351
≥ 500 3103 63,973 836.3 250
Age at hospitalization
< 1 year 7585 226,939 3142 1055
1 year 484 7696 126.0 22
2–4 years 2422 34,130 510.1 42
5–12 years 531 6753 121.4 18
> 12 years 100 1509 29.3 8
Fig. 2 Relationship of Mortality Related Resource Utilization Fraction
with Calendar Year from the Pediatric Health Information System
2004–2013. No significant association was found between calendar
year and mortality related resource utilization fraction in hypoplastic
left heart syndrome, either in the billed charges domain (upper
panel) or in the length of stay domain (lower panel)
Fig. 3 Relationship of Mortality Related Resource Utilization Fraction
with Institutional Volume from the Pediatric Health Information
System 2004–2013. In hypoplastic left heart syndrome, there was no
significant association between institutional volume and mortality
related resource utilization fraction, either in the billed charges
domain (upper panel) or in the length of stay domain (lower panel)
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disclosed a high rate of complications from staged palli-
ation of HLHS [16–21], including demise at home after
hospital dismissal, neurologic sequelae, developmental
delays, and a need in some instances for complex sup-
portive home health care. Inpatient death, the outcome
evaluated in this analysis, is therefore somewhat limited
measure of the ways in which things can go wrong in
HLHS care. No doubt MRRUF substantially underesti-
mates the larger problem of investment more generally
in poor outcomes, manifesting as they might not only as
inpatient deaths, but also as later deaths and severe non-
fatal morbidities. Nevertheless, even when the unsuc-
cessful care is defined only by the insensitive measure of
inpatient mortality, MRRUF in the care of HLHS is not
small.
On a more general health policy level, the cost of care
for young patients with poor prognosis from chronic
conditions (cardiac and noncardiac) has attracted in-
creasing interest in recent years [3, 22–24]. End of life
care in general is known to be expensive, so it is not sur-
prising that we find this is true for HLHS. Concerns are
appropriately raised that even high levels of investment
in their care may not be optimally directed toward
meeting their actual needs. HLHS certainly qualifies as
this kind of complex chronic condition, and the results
reported here suggest at least the possibility that current
patterns of investment in care may not be ideal. The on-
going search for factors associated with poor outcomes
in HLHS [25, 26] may identify ways to selectively alter
the approach to best serve the patients’ needs. Surgical
complexity has been identified as a risk factor for high
resource utilization, with an incremental increase in
odds demonstrated for higher resource utilization with
higher surgical risk categories [25].
Others have shown that hospital costs in patients
undergoing congenital heart surgery vary significantly
from center to center. These differences were most pro-
nounced for lower complexity surgeries, and hospital
surgical volume appeared to play a role [27]. It is note-
worthy that MRRUF also did not vary significantly with
institutional volume either in the billed charges domain
or in the length of stay domain, even when potentially
outlying extreme low volume institutions were excluded.
Low institutional MRRUF might or might not reflect
excellence in care of HLHS. It could result from low
mortality or efficient resource utilization in hopeless
cases, both of which are desirable. On the other hand, it
might just as easily result from institutional tendencies
not to offer aggressive care for higher risk patients who
might still benefit, or to give up too soon in the face of
potentially fatal complications when a favorable outcome
might still result from prolonged, expensive care. We
therefore acknowledge that the ideal institutional
MRRUF in the current era of HLHS care remains un-
known, and do not argue that care for HLHS should be
concentrated in centers with low institutional MRRUF.
Limitations and future directions
The focus of this investigation was the development of the
MRRUF index and its application to a specific clinical
circumstance (HLHS). Two sources of potential variation
in MRRUF were selected for more detailed analysis: (1)
volume of HLHS admissions at the hospital providing
care, and (2) patient age, as intensity of HLHS care varies
somewhat predictably with age. This does not include ana-
lysis of MRRUF as a function of other potentially interest-
ing socioeconomic markers like insurance status, race,
and ethnicity. Although it stands to reason that particular
surgical interventions undertaken during hospitalization
would influence MRRUF via surgical mortality, it was
beyond the scope of this pilot work to perform subanalysis
of MRRUF based on surgical codes. This initial report is
limited to HLHS, however our group is currently actively
developing comparisons using PHIS datasets representing
other common congenital cardiac defects. Future investi-
gation of the role of comorbidities, including prematurity,
genetic syndromes, and anomalies of other organ systems
Fig. 4 Mortality Related Resource Utilization Fraction and Mortality
rate by Age Category from the the Pediatric Health Information
System 2004–2013. Inpatient mortality and mortality related resource
utilization fraction in hypoplastic left heart syndrome were higher
among the 14–21 year olds, and those under a year old than
among those of intermediate ages
Table 2 Comparisons of inpatient mortality rates and mortality-
related resource utilization fraction in hypoplastic left heart
syndrome (Pediatric Health Information System, 2004–2013)
Age (years) N Deaths (%) Length of stay Billed charges
<1 7585 13.9 0.178 0.238
1 484 4.5 0.121* 0.135*
2–4 2422 1.7 0.057* 0.083*
5–12 531 3.3 0.076* 0.111*
>12 100 8.0 0.185 0.220
*Indicates p < 0.05 relative to age < 1 year
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on MRRUF in HLHS and other congenital cardiac defects
could provide useful data. Tracking individual patients
across admissions at multiple institutions is possible so
long as the institutions are PHIS participants, but for the
sake of simplicity and clarity this analysis was done at the
hospital admission level, not at the individual patient level.
Even as comprehensive an administrative database as
PHIS lacks some clinical detail, and analyses such as this
leave many interesting questions unanswered. The inves-
tigators depend on the accuracy of coding and data
entry, but do not have direct quality control over either.
It is well recognized that billed charges and reimburse-
ment are not easily convertible to actual costs [28]. The
MRRUF, normalized as it is to total investment, does not
suffer from the inaccuracies of conversion from billed
charges to actual costs, nor is it subject to distortion
from inflation. However, as MRRUF is not a cost meas-
ure per se, it cannot be incorporated into a classic cost-
benefit analysis. The study is limited to investments in
care of HLHS, and cannot be extrapolated to the care of
congenital heart disease in general. The investigators
recognize that investment in inpatient fatality occurs in
the care of other forms of congenital heart disease, but
the results reported here carry no specific implications
beyond HLHS.
Conclusions
In conclusion, the mortality-related resource utilization
fraction is very high in HLHS, and it shows no sign of
falling with the passage of time, even as mortality rates
gradually improve. This phenomenon is observed across
institutions of all volumes of practice. Mortality-related
resource utilization in HLHS is high in the very young,
but peaks again to high levels in late childhood. Regard-
less of the large fraction of resource utilization in HLHS
care that does not produce survivors, this analysis must
not be construed as an argument against sophisticated
invasive surgical palliative management of HLHS. In-
stead, these findings highlight the need for data-driven
critical review of standard practices to identify patterns
of care associated with success with HLHS, and to mod-
ify approaches objectively. Remarkable as the advances
have been since the days when comfort measures were
all that could be offered, inpatient care of HLHS carries
with it substantial mortality- related resource utilization.
We speculate that clinical investigations designed to dis-
cover more optimal inpatient care strategies may result
in reduction in both mortality and resource utilization.
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